Clinical Context and Decision-Making Surrounding Early Discontinuation of Adjuvant Immune Checkpoint Inhibitors in Genitourinary Malignancies: A Real-World Cohort Study
Abstract Purpose Adjuvant immune checkpoint inhibitors (ICIs) are increasingly used for genitourinary malignancies after curative-intent surgery; however, real-world treatment persistence and the circumstances surrounding early discontinuation are unclear. We evaluated treatment completion and the clinical circumstances and decision-making surrounding permanent discontinuation. Methods We retrospectively evaluated 39 consecutive patients who were administered adjuvant pembrolizumab for renal cell carcinoma or nivolumab for urothelial carcinoma at a single center from 2022 to 2025; the data cut-off date was October 8, 2026. The primary outcome was the completion of a planned 1-year treatment among patients with a definitive completion status. The two cohorts were analyzed descriptively without direct comparison. Results Of 37 patients with a definitive treatment status, 20 completed planned therapy (54.1%; 95% confidence interval, 36.9–70.5%) and 17 permanently discontinued treatment before completion (45.9%). The remaining two patients (5.1% of 39) were still on treatment at data cut-off. An adverse event was the documented primary reason for discontinuation in 12 of 17 patients (70.6%); 11 of these 12 (91.7%) followed Grade 1–2 events. Patient preference contributed to nine of 17 discontinuations (52.9%) through patient-initiated or shared decision-making. Grade ≥ 3 adverse events occurred in two patients (5.1%). Conclusions In this retrospective cohort, permanent discontinuation of adjuvant ICI therapy was frequently documented in association with low-grade toxicity and with patient preference, whereas Grade ≥ 3 toxicity was uncommon. Shared decision-making that balances anticipated recurrence-risk reduction against treatment burden represents an important consideration in individualizing adjuvant immunotherapy.
Authors
- Atsushi Yanase
- Masayuki Kurokawa (ORCID: https://orcid.org/0000-0002-6901-6735)
- Toru Sugihara (ORCID: https://orcid.org/0000-0002-0901-3209)
- Eiichiro Takaoka (ORCID: https://orcid.org/0000-0002-1814-8949)
- Hayato Hoshina (ORCID: https://orcid.org/0009-0009-5067-0241)
- Tetsuya Fujimura (ORCID: https://orcid.org/0000-0002-3421-8273)
- Haruki Kume
Institutions
- Jichi Medical University Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11575221/v1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- preprint